Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2022-02-15 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
上市保荐书（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled '上市保荐书' which translates to 'Listing Sponsorship Letter' or 'Sponsorship Document' related to a specific stock issuance by Beijing Northland Biotech Co., Ltd. It contains detailed information about the company, its business, products, clinical trials, financial data, risks, and the use of raised funds. The document is issued by a securities company as the sponsor for a specific stock issuance to particular investors. It is not a general annual report, earnings release, or management discussion. It is a formal regulatory filing related to a capital raising event (private placement or directed share issuance). The document is lengthy (15,000 characters) and contains substantive information about the issuance and company background, consistent with a Capital/Financing Update. It is not a report publication announcement or a proxy statement. Therefore, the best fitting category is Capital/Financing Update (CAP).
2022-02-15 Chinese
重要在研产品项目取得阶段性成果公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Beijing Northland Biotech Co., Ltd. regarding the interim results of a clinical trial project (Phase IIa) for a drug candidate. It includes details about the clinical trial design, preliminary results, safety data, and the company's plans for further trials. The document explicitly states that the clinical trial results are preliminary and that there is no significant short-term financial impact. It also includes a risk warning to investors. The document is relatively short (995 characters) and is an announcement of clinical trial progress rather than a financial report or regulatory filing related to financial performance or governance. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings related to financial or governance matters. The content is focused on clinical trial progress and its impact on the company, which is typical for a Regulatory Filings (RNS) category in the context of corporate announcements that do not fit other specific financial or governance categories.
2022-01-25 Chinese
关于接待机构投资者调研情况的公告
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the reception of institutional investor research and includes a Q&A about a specific private placement of shares (向特定对象发行股票) and related fundraising purposes, pricing, and project progress. It is not a full financial report, earnings release, or management discussion. The document length is short (1682 characters) and it mainly provides information about investor engagement and fundraising details. This fits best under Capital/Financing Update (CAP) as it discusses a private placement and fundraising activities.
2021-12-28 Chinese
股票解除限售公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the lifting of stock trading restrictions (解除限售公告) for certain shares held by a former director. It details the number of shares becoming tradable, reasons for lifting restrictions, and related shareholder commitments. There is no financial data, earnings, or report content. The document is a regulatory announcement about share status changes, specifically about share lock-up release, which fits the category of Share Issue/Capital Change (SHA) as it relates to changes in share capital conditions and tradability.
2021-12-26 Chinese
关于向特定对象发行股票申请获得北京证券交易所受理的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (553 characters) regarding the acceptance by the Beijing Stock Exchange of the company's application for a private placement of shares. It mentions the receipt of an acceptance notice and states that the issuance is subject to further approvals. There is no detailed financial data or report content, only an update on the capital raising process. This fits the definition of a Capital/Financing Update (CAP) rather than a full report or regulatory filing. The document is not a report publication announcement since it does not mention any report being published or attached.
2021-12-22 Chinese
2021年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 2021 third extraordinary general meeting of shareholders of Beijing Northland Biotech Co., Ltd. It includes information about the meeting date, attendance, agenda items, voting results, and legal opinions. The main content revolves around shareholder approvals for a private placement of shares to specific investors, including the issuance plan, pricing, quantity, use of proceeds, and authorization of the board to handle related matters. The document is not a full financial report, audit, or earnings release, but rather a formal announcement of shareholder meeting decisions and voting outcomes. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is sufficient and contains substantive voting details, not just a brief notice or a report publication announcement. Therefore, the classification is DVA with high confidence.
2021-12-19 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.